FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab June 14, 2022
Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved June 13, 2022
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
First patient dosed with ADG106 + ADG116 combination in Ph 1b/2 trial in solid tumors January 28, 2022
First Patient Treated in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer April 21, 2021
